Axios – “Pfizer yesterday took a giant step toward a COVID-19 vaccine, reporting that its vaccine candidate was effective in over 90% of uninfected clinical trial patients. Reality check: It’s a giant and welcome development, but the pandemic will be with us long after vaccine distribution begins. The Pfizer vaccine is not a silver bullet. Its efficacy is much higher than the 50% threshold set by the U.S. Food & Drug Administration (FDA), but could still leave tens of millions of vaccinated Americans at risk. This means that many pandemic protocols are likely to remain in place, either by law or by habit, and some businesses already are preparing for this new normal — including startups that developed new products and services during the pandemic…”